info@seagull-health.com

SeagullHealth

语言:

Homepage

Drugs

Pacritinib(Vonjo)

Names

帕克替尼

Indicatons

Treatment of intermediate or high-risk primary or secondary myelofibrosis in adults with severe thrombocytopenia...

Price:

Manufacturer:

BIOVITRUM AB

Dosage form:

CAPSULE

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Vonjo(Pacritinib) Instructions:Uses,Dosage, Side Effects

VONJO (pacritinib) is a prescription kinase inhibitor supplied as 100 mg capsules. It is characterized by its distinct mechanism of action, which selectively targets key kinases like JAK2, FLT3, and IRAK1 without inhibiting JAK1. This profile positions it as a specialized therapeutic option for managing myelofibrosis in adults presenting with significant thrombocytopenia, a condition where treatment choices are often limited.

Generic name

Pacritinib(Vonjo)

English name

Pacritinib

Alternative Names

帕克替尼

Drug prices

Indications

VONJO is indicated for the treatment of adult patients with intermediate or high-risk primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera or post-essential thrombocythemia) who have a baseline platelet count below 50 × 10⁹/L. This approval was granted under an accelerated pathway based on the endpoint of spleen volume reduction.

Therapeutic Target

JAK2,mutant JAK2V617F,FLT3,IRAK1,ACVR1/ALK2.CSF1R

Active Ingredients

Pacritinib citrate.

Dosage Form

CAPSULE

Specifications

100mg * 120 capsules/box

Dosage and Administration

The standard dosage is 200 mg (two 100 mg capsules) taken orally twice daily.

Related Columns

Recommended articles

Side effects and adverse reactions of Pacritinib

Pacritinib is used to treat myelofibrosis with low platelets. During treatment, various adverse reactions may occur, and monitoring should focus on bleeding, gastrointestinal, and cardiovascular event...

Dietary precautions for patients with Pacritinib

During oral treatment with pacritinib, diet is closely related to the method of administration, gastrointestinal reactions, and concomitant medications. Patients should pay attention to the following ...

Special population use of Pacritinib

Pacritinib is used in adult patients with myelofibrosis and a platelet count below 50×10⁹/L. For use in special populations, attention should focus on hepatic function, renal function, pregnancy, lact...

Pacritinib (Vonjo) Precautions for Administration

Pacritinib is a JAK2/FLT3 inhibitor used for the treatment of splenomegaly or symptoms associated with myelofibrosis.I. Patient Assessment Before Treatment1. Platelet Count Assessment(1) Baseline plat...

How to Use Vonjo (Pacritinib)

Vonjo (pacritinib) is an oral kinase inhibitor approved by the U.S. FDA in 2022. It is specifically indicated for the treatment of adult patients with intermediate- or high-risk primary or secondary (...

What is Vonjo (Pacritinib)?

Vonjo (pacritinib) is a novel kinase inhibitor approved by the U.S. Food and Drug Administration (FDA), providing a new treatment option for patients with specific types of myelofibrosis.What is Vonjo...

Departments